Precision Analytic Research Methods in OCD

October 21, 2025 updated by: Amy Rapp, Icahn School of Medicine at Mount Sinai

Dissecting Neurocognitive Components of Compulsivity Using Computational Modeling and EEG

Psychiatric disorders characterized by compulsivity, such as obsessive-compulsive disorder (OCD), result in considerable functional impairment and many individuals do not respond to gold-standard treatments. Compulsivity has long been thought to occur due to exaggerated habits and reduced goal-directed control, although more recently, this conceptualization of compulsivity as an imbalance of two cognitive systems has been challenged as overly narrow. This study will recruit 100 individuals (50 adults diagnosed with OCD, 50 healthy controls) and leverage the measurement precision offered by theory-driven computational modeling in combination with electroencephalogram (EEG) to go beyond this binary theory of compulsivity, revealing how more complex interactions of neurocognitive subcomponents contribute to compulsivity-information that could ultimately lead to improved treatment personalization and clinical outcomes.

Study Overview

Status

Recruiting

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • New York
      • New York, New York, United States, 10029
        • Recruiting
        • Icahn School of Medicine at Mount Sinai
        • Principal Investigator:
          • Amy Rapp

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Participants must be:

  • between the ages 18-55 years old
  • English-speaking
  • right-handed
  • able to provide consent

Exclusion Criteria:

Individuals diagnosed with OCD will be excluded if:

  • they meet diagnostic criteria for certain other psychiatric disorders
  • are taking psychiatric medication or have received behavioral treatment for OCD within a certain timeframe
  • if it is unsafe for them to participate in research

Healthy control participants will be excluded if:

  • they have a current psychiatric disorder
  • a lifetime history of certain psychiatric disorders
  • are taking psychiatric medication or have in the past
  • have a parent or sibling who has been diagnosed with OCD
  • if it is unsafe for them to participate in research

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Participants diagnosed with OCD
All participants diagnosed with Obsessive Compulsive Disorder (OCD) who enroll in this study will receive 17 sessions of exposure and response prevention, a specialized cognitive behavioral therapy for OCD, over the course of 10 weeks.
Exposure and response prevention (EX/RP) is the gold-standard behavioral treatment for OCD. It involves confronting the content of obsessions (distressing thoughts, images, or impulses) and resisting the urge to engage in compulsions (observable behaviors or mental acts that are repeated to reduce the anxiety/distress associated with compulsions).
No Intervention: Healthy controls
Individuals who do not have a current or lifetime psychiatric diagnosis will not receive any treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Yale Brown Obsessive Compulsive Scale
Time Frame: Week 1, Week 5, Week 10
A semi-structured clinician-administered instrument used to measure obsessions and compulsions separately over five dimensions (time consumed, distress, interference, degree of resistance, control). The range of scores for the Obsessions and Compulsions subscales is 0-20, and the range for the total score is 0-40. Higher scores indicate greater symptom severity, and a total score greater or equal to 16 is considered indicative of moderately severe OCD
Week 1, Week 5, Week 10

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Obsessive Compulsive Inventory- Revised
Time Frame: Week 1, Week 5, Week 10
An 18-item self-report measure to assess obsessions and compulsions that demonstrates good psychometric properties and has been used in other research as a transdiagnostic measure of compulsivity. The range of scores for the six subscales (Washing; Obsessing; Ordering; Checking; Neutralizing; Hoarding) is 0-12. The range for the total score is 0-60 and does not include the Hoarding subscale. Higher scores indicate greater symptom severity.
Week 1, Week 5, Week 10
Cambridge-Chicago Compulsivity Trait Scale
Time Frame: Week 1, Week 5, Week 10
A 15-item self-report measure to assess compulsivity transdiagnostically that exhibits high internal consistency and excellent convergent validity with gold-standard measures of compulsive symptoms. The range for the total score is 0-45, with higher scores indicating greater symptom severity
Week 1, Week 5, Week 10
Self-Report Habit Index
Time Frame: Week 1, Week 5, Week 10
A 12-item self-report measure of the repetition and automaticity of a behavior that exhibits high internal consistency and test-retest reliability. The range for the total score is 12-84, with higher scores indicating greater symptom severity.
Week 1, Week 5, Week 10
Dimensional Obsessive- Compulsive Scale
Time Frame: Week 1, Week 5, Week 10
A 20-item self-report measure that assesses four of the most consistently replicated thematic dimensions of OCD symptoms (i.e., contamination, harm, symmetry, repugnant content). The DOCS demonstrates good to excellent internal consistency, validity, and sensitivity. The range of scores for the four subscales (Contamination; Harm; Unacceptable Thoughts; Symmetry) is 0-20, and the range for the total score is 0-80. Higher scores indicate greater symptom severity.
Week 1, Week 5, Week 10

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Amy Rapp, PhD, Icahn School of Medicine at Mount Sinai

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 9, 2025

Primary Completion (Estimated)

March 31, 2030

Study Completion (Estimated)

March 31, 2030

Study Registration Dates

First Submitted

June 2, 2025

First Submitted That Met QC Criteria

June 2, 2025

First Posted (Actual)

June 10, 2025

Study Record Updates

Last Update Posted (Actual)

October 23, 2025

Last Update Submitted That Met QC Criteria

October 21, 2025

Last Verified

October 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY-24-01125
  • K23MH133997 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All of the individual participant data collected during the trial, after deidentification.

IPD Sharing Time Frame

Deidentified data will be deposited to the Open Science Framework (OSF) and the NIMH Data Archive (NDA), in line with data sharing requirements stipulated by the NIMH. In addition to the patient level data, experimental task design specifications will be shared to OSF and posted on the Principal Investigator's (Amy Rapp) GitHub page. A data dictionary will be uploaded to the NDA. Researchers who are interested in obtaining data from this study to submit a written request which would allow access for one year and would be renewable. Deidentified data will be stored indefinitely in the NDA.

IPD Sharing Access Criteria

Researchers who provide a methodologically sound proposal will be given access to deindentified study data needed to achieve aims in the approved proposal. Data will be available indefinitely at site link (to be determined).

IPD Sharing Supporting Information Type

  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe